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Objective: Functional Electrical Stimulation is used to improve walking speed and 
reduce falls in people with upper motor neurone foot drop. Following anecdotal 
observations of changes in bladder symptoms, an observational study was 
performed to explore this association further.   
Design: 47 consecutive patients attending for set up with Functional Electrical 
Stimulation during a six month period were asked to complete a questionnaire 
assessing bladder symptoms (ICIQ-OAB) at baseline and 3 months during routine 
appointments. 
Subjects: 35 (75%) had multiple sclerosis, the other 12 subjects had a total of 9 
diagnoses including 3 with stroke. Other conditions included cerebral palsy, motor 
neurone disease, hereditary spastic paraparesis, meningioma and spinocerebellar 
ataxias. 
Results: Improvement in over active bladder symptoms was not significant in the 
whole cohort however was in patients with multiple sclerosis (n=35; mean change in 
ICIQ-OAB score 1.0, p= 0.043).  Specifically, significant improvements were seen in 
urgency and urge incontinence in multiple sclerosis patients. There was a significant 
negative correlation of moderate strength within the multiple sclerosis cohort 
between baseline walking speed and subsequent change in ICIQ-OAB score 
(correlation coefficient of r=-0.40, p=0.046). Thus greater changes in bladder 
symptoms were seen with lower baseline walking speeds. 
Conclusion: The results of this exploratory study suggest that Functional Electrical 
Stimulation use does improve over active bladder symptoms in people with multiple 
































































sclerosis. Further exploration is needed to study this association and explore 
whether the mechanism is similar to that of Percutaneous Tibial Nerve Stimulation, a 
recognised treatment for the over active bladder.   
 

































































Functional Electrical Stimulation is a recognised management strategy for people 
with foot drop secondary to an upper motor neurone disorder, approved as effective 
by the UK National Institute for Health and Clinical Excellence (NICE). 1 Surface skin 
electrodes are placed over the Common Peroneal Nerve and/or the tibialis anterior 
muscle activating the dorsiflexors and evertors, thus improving the ability to clear the 
foot during swing phase of gait; improving stability and reducing falls.2  
Percutaneous Tibial Nerve Stimulation has been shown to be a safe, clinically and 
cost-effective treatment (also NICE approved) for the management of drug refractory 
overactive bladder symptoms in people with neurological disorders. 3-6 It involves 
inserting a stimulating needle 3 fingerbreadths above the medial malleolus close to 
the Tibial Nerve and placing a surface electrode on the same leg near the arch of the 
foot. Most treatment schedules consist of 12 outpatient sessions lasting 30 minutes 
each (adjustable pulse intensity 0–10mA, fixed pulse width of 200 microseconds, 
frequency 20Hz).3,4 The mechanism by which Percutaneous Tibial Nerve Stimulation 
works to improve bladder dysfunction remains uncertain. It is likely that stimulation of 
a somatic peripheral nerve results in alteration of signaling centrally in the spinal 
cord interneurons and peripherally at sympathetic and parasympathetic 
postganglionic nerve terminals and synapses involved in the voiding reflex, thereby 
resulting in an alteration of bladder functions.7,8  
In our experience some patients report improvement in lower urinary tract symptoms 
after the commencement of Functional Electrical Stimulation to aid walking. The 
Tibial and Common Peroneal nerves are the terminal branches of the sciatic nerve, 
both are derived from L4-S3 sharing a common innervation, we therefore 
































































hypothesise that Functional Electrical Stimulation may have effects on lower urinary 
tract  functions similar to Percutaneous Tibial Nerve Stimulation treatment.  We 
therefore studied our clinic population for any possible relationship between the use 
of Functional Electrical Stimulation and changes in bladder symptoms, to inform the 
design of a future study. 
 
Methods 
Consecutive patients attending for set up with Functional Electrical Stimulation using 
the Odstock Dropped Foot Stimulator (ODFS®) Pace device (single channelled, foot 
switch triggered: maximum amplitude 100mA, 350µs pulse, 40Hz) during a six month 
period were asked to complete a qu stionnaire on their urinary functions at baseline 
and 3 months during their routine physiotherapy appointments. The ICIQ-OAB 
questionnaire provides a brief and robust measure to assess the impact of 
overactive bladder symptoms. It is scored from 0-16 with greater values indicating 
increased symptom severity of urinary frequency, urgency, nocturia and urinary 
incontinence.9,10 
No further details were collected regarding bladder management and this continued 
as normal practice. The service evaluation was reviewed and registered with the 
Clinical Governance Department.  
 
Statistical Analysis 
Data was analysed using SPSS; the Wilcoxon Signed-Rank Test was used to 
compare ICIQ-OAB scores at baseline and 3 months and Spearman’s Rank 
































































Correlation Coefficient to assess the relationship between baseline walking speed 
and ICIQ-OAB scores with change in ICIQ-OAB scores. 
 
Results 
Of the 47 subjects proceeding to Functional Electrical Stimulation set up within the 6 
month period 35 (75%) had a diagnosis of multiple sclerosis, the other 12 subjects 
had a total of 9 diagnoses including 3 with stroke. Other conditions included cerebral 
palsy, motor neurone disease, hereditary spastic paraparesis, meningioma and 
spinocerebellar ataxias. 
There was a significant improvement of the ICIQ-OAB score (a reduction in score 
indicates an improvement in bladder symptoms) in the multiple sclerosis population 
over the 3 month period (p=0.043).  When urinary symptoms were separately 
analysed, significant improvements were seen in urgency and urge incontinence 
(Table 1).  
There was a significant negative correlation of moderate strength in multiple 
sclerosis patients between baseline walking speed and the subsequent change in 
ICIQ-OAB score (correlation coefficient of r=-0.40, p=0.046). Thus greater 
improvements in bladder symptoms were seen with lower baseline walking speeds 
(Figure 1). 
With respect to bladder impairment, a significant negative correlation of moderate 
strength was shown between baseline ICIQ-OAB score and change in score; thus 
patients with worse bladder symptoms at baseline had smaller improvement in ICIQ-
































































OAB scores (Whole group r=-0.466, p=0.001, multiple sclerosis group r=-0.442, 
p=0.008) (Figure 2).  
 
Discussion 
The results of this study demonstrate a statistically significant improvement in 
overactive bladder symptoms after 3 months of functional electrical stimulation use 
to improve walking in multiple sclerosis patients. The one unit reduction (17%) 
observed reflects a rec gnised clinically important difference.11 
When individual symptoms of bladder dysfunction were considered, the main areas 
demonstrating improvement were urinary urgency and urge incontinence. The 
impact of bladder dysfunction may of course be influenced by improvements in 
mobility and speed of accessing toileting facilities particularly with regard to 
incontinence. However it is unlikely that participants would report changes in urgency 
simply as a result of an orthotic effect on their walking. It would however be 
invaluable to correlate these findings with objective evidence of improvements in 
urinary dysfunction through urodynamic studies. 
Despite significant changes in the sub-scores of the ICIQ-OAB assessing urinary 
urgency and urge incontinence, the change in overall score was not significant when 
all patients were considered together. We postulate that this may reflect the 
differences in the neurological insult; multiple sclerosis has a heavy burden of spinal 
cord pathology whereas the other group was predominantly comprised of cerebral 
origin disorders. This association is perhaps borne out further by the significant 
correlation within the multiple sclerosis cohort between baseline walking speed and 
































































the subsequent change in ICIQ-OAB score, demonstrating that perhaps those 
patients with a higher spinal cord disease burden (slower walking speeds) had 
greater improvement in overactive bladder symptoms. Studies of Percutaneous 
Tibial Nerve Stimulation have also demonstrated particular efficacy in patients with 
multiple sclerosis and for all aspects of their urinary symptoms,12,13  
Analysis revealed a significant negative moderate correlation between baseline 
ICIQ-OAB score and change in score, demonstrating that people with less severe 
bladder symptoms at baseline were more likely to show improvements following 
Functional Electrical Stimulation use. This warrants further investigation with 
urodynamic studies but is an interesting observation as it suggests individuals with 
mild urinary symptoms may be able to avoid drug treatments and be managed solely 
through neuromodulation. 
The mode of delivery of Percutaneous Tibial Nerve Stimulation and Functional 
Electrical Stimulation clearly differ. Percutaneous Tibial Nerve Stimulation is usually 
delivered as a course of weekly 30 minute treatment sessions over 12 weeks giving 
a total dosage of 6 hours in 3 months, whereas Functional Electrical Stimulation may 
deliver this much in a single day albeit of a reduced intensity. This study did not 
collect information on dosage (step count) or intensity (amplitude), two important 
aspects to consider in future study designs.   
This is an observational study and has limitations, a further study designed to 
specifically evaluate efficacy with pathophysiological correlates including 
urodynamics is warranted. We do not propose that Functional Electrical Stimulation 
be used to treat urinary symptoms but it does however for the first time indicate that 
its use may improve bladder dysfunction and could have implications for 




































































• Functional Electrical Stimulation to aid walking may improve neurogenic 
bladder symptoms particularly in patients with multiple sclerosis 
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Subject demographic and ICIQ-OAB Scores 
 All 
n=47 








52 (37-70) 49 (32-66) 































































































*Significant change p<0.05 
MS multiple sclerosis; SD standard deviation; IQR= Interquartile range; 
 
  


































































Figure 1. Scatterplot of baseline walking speed and change in ICIQ-OAB score in 
multiple sclerosis subjects 
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